Sandoz inaugurates BioInject — a new biopharmaceutical manufacturing facility in Schaftenau, Austria

BioInject is a state-of-the-art facility that will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics.

BioInject is a state-of-the-art facility that will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics. This new facility now means that 18,000 syringes can be filled and 100 packaged per minute. It will play an important role in driving the next wave of biosimilars and novel biologics growth at Sandoz and Novartis Pharmaceuticals — growth that will ultimately help address unmet medical needs and broaden patient access to key biologics products.

Welcoming guests at the event, Carol Lynch, Global Head of Biopharmaceuticals and Oncology Injectables at Sandoz said: “BioInject stands as a testament to both Sandoz’s technological leadership in biologics, as well as the company’s commitment to further strengthening its global leadership in biosimilars.” BioInject will become a central part of Novartis’ biomanufacturing network which also includes facilities in Slovenia, Singapore and France.